Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Ovarian Cancer | Research

Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center

Authors: Cancan Duan, KuoKuo Li, Xiaohua Pan, Zhaolian Wei, Lan Xiao

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

The potential treatment effects of heat shock protein 90 (Hsp90) inhibitors in ovarian cancer (OC) are controversial. This research aims to investigate the relationship between the level of Hsp90 in peripheral blood and the prognosis of OC patients, as well as the clinicopathological indicators.

Materials and methods

We retrospectively collected the clinicopathological indicators of OC patients who were admitted to the Department of Obstetrics and Gynecology of the First Affiliated Hospital of Anhui Medical University from 2017 to 2022. Hsp90 level in patient blood was detected by enzyme-linked immunosorbent assay, and the correlation between Hsp90 level and OC prognosis was systematically investigated. Kaplan–Meier method was used to draw the survival curve, and the average survival time and survival rate were calculated. The log-rank test and Cox model were used for univariate survival analysis, and the Cox proportional hazards model was applied for multivariate survival analysis. Based on the TCGA dataset of OC obtained by cBioPortal, Pearson’s correlation coefficients between Hsp90 level values and other mRNA expression values were calculated to further conduct bioinformatics analysis. GSEA and GSVA analysis were also conducted for gene functional enrichment. The expression of Hsp90 in OC tissues were evaluated and compared by Immunohistochemical staining.

Results

According to the established screening criteria, 106 patients were selected. The enzyme-linked immunosorbent assay results showed that 50.94% OC patients with abnormal Hsp90 level. According to the outcome of Kaplan–Meier curves, the results revealed that the abnormal level of Hsp90 was suggested to poor prognosis (P = 0.001) of OC patients. Furthermore, the result of multivariate Cox proportional hazards regression model analysis also predicted that abnormal Hsp90 level (HR = 2.838, 95%CI = 1.139–7.069, P = 0.025) was linked to poor prognosis, which could be an independent prognostic factor for the prognosis of OC patients. Moreover, top 100 genes screened by Pearson’s value associated with Hsp90, indicating that Hsp90 participated in the regulation of ATF5 target genes, PRAGC1A target genes and BANP target genes and also enriched in the metabolic processes of cell response to DNA damage stimulus, response to heat and protein folding.

Conclusion

Hsp90 level is positively associated with OC mortality and is a potential prognostic indicator of OC.

Torre LA, Trabert B, DeSantis CE, et al. OC statistics, 2018. CA Cancer J Clin. 2018;68(4):284–96. https://doi.org/10.3322/caac.21456.CrossRefPubMedPubMedCentral

Reid BM, Permuth JB, Sellers TA. Epidemiology of OC: a review. Cancer Biol Med. 2017;14(1):9–32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084.CrossRefPubMedPubMedCentral

Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking OC: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719–25. https://doi.org/10.1038/nrc3144.CrossRefPubMedPubMedCentral

Hartnett J, Thom B, Kline N. Caregiver burden in end-stage OC. Clin J Oncol Nurs. 2016;20(2):169–73. https://doi.org/10.1188/16.CJON.169-173.CrossRefPubMedPubMedCentral

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. OC. Nat Rev Dis Primers. 2016;2:16061. https://doi.org/10.1038/nrdp.2016.61

OC Research Alliance, OC Statistics, https://ocrahope.org/patients/about-ovarian-cancer/recurrence/.

Chu CS, Kim SH, June CH, Coukos G. Immunotherapy opportunities in OC. Expert Rev Anticancer Ther. 2008;8(2):243–57. https://doi.org/10.1586/14737140.8.2.243.CrossRefPubMed

Sima S, Richter K. Regulation of the Hsp90 system. Biochim Biophys Acta Mol Cell Res. 2018;1865(6):889–97. https://doi.org/10.1016/j.bbamcr.2018.03.008.CrossRefPubMed

Prodromou C. Mechanisms of Hsp90 regulation. Biochem J. 2016;473(16):2439–52. https://doi.org/10.1042/BCJ20160005.CrossRefPubMed

10.

Pearl LH. Hsp90 and Cdc37 – a chaperone cancer conspiracy. Curr Opin Genet Dev. 2005;15(1):55–61. https://doi.org/10.1016/j.gde.2004.12.011.CrossRefPubMed

11.

Horejsí Z, Takai H, Adelman CA, et al. CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability. Mol Cell. 2010;39(6):839–50. https://doi.org/10.1016/j.molcel.2010.08.037.CrossRefPubMed

12.

Takai H, Xie Y, de Lange T, Pavletich NP. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. Genes Dev. 2010;24(18):2019–30. https://doi.org/10.1101/gad.1956410.CrossRefPubMedPubMedCentral

13.

Pratt WB, Morishima Y, Murphy M, Harrell M. Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol. 2006;172:111–38. https://doi.org/10.1007/3-540-29717-0_5.CrossRef

14.

Pratt WB. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med. 1998;217(4):420–34. https://doi.org/10.3181/00379727-217-44252.CrossRefPubMed

15.

Makhnevych T, Houry WA. The role of Hsp90 in protein complex assembly. Biochim Biophys Acta. 2012;1823(3):674–82. https://doi.org/10.1016/j.bbamcr.2011.09.001.CrossRefPubMed

16.

Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature. 1998;396(6709):336–42. https://doi.org/10.1038/24550.CrossRefPubMed

17.

Lindquist S. Protein folding sculpting evolutionary change. Cold Spring Harb Symp Quant Biol. 2009;74:103–8. https://doi.org/10.1101/sqb.2009.74.043.CrossRefPubMed

18.

Yahara I. The role of HSP90 in evolution. Genes Cells. 1999;4(7):375–9. https://doi.org/10.1046/j.1365-2443.1999.00271.x.CrossRefPubMed

19.

Williams TA, Fares MA. The effect of chaperonin buffering on protein evolution. Genome Biol Evol. 2010;2:609–19. https://doi.org/10.1093/gbe/evq045.CrossRefPubMedPubMedCentral

20.

Seigneuric R, Mjahed H, Gobbo J, et al. Heat shock proteins as danger signals for cancer detection. Front Oncol. 2011;1:37. https://doi.org/10.3389/fonc.2011.00037.CrossRefPubMedPubMedCentral

21.

Cheng Q, Chang JT, Geradts J, et al. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 2012;14(2):R62. https://doi.org/10.1186/bcr316820.CrossRefPubMedPubMedCentral

22.

Hance MW, Dole K, Gopal U, et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem. 2012;287(45):37732–44. https://doi.org/10.1074/jbc.M112.389015.CrossRefPubMedPubMedCentral

23.

Li J, Buchner J. Structure, function and regulation of the hsp90 machinery. Biomed J. 2013;36(3):106–17. https://doi.org/10.4103/2319-4170.113230.CrossRefPubMed

24.

Chun JN, Choi B, Lee KW, et al. Cytosolic Hsp60 is involved in the NF-kappaB-dependent survival of cancer cells via IKK regulation. PLoS One. 2010;5(3):e9422. https://doi.org/10.1371/journal.pone.0009422.CrossRefPubMedPubMedCentral

25.

Park HK, Lee JE, Lim J, Kang BH. Mitochondrial Hsp90s suppress calcium-mediated stress signals propagating from mitochondria to the ER in cancer cells. Mol Cancer. 2014;13:148. https://doi.org/10.1186/1476-4598-13-148.CrossRefPubMedPubMedCentral

26.

Wu AH, Pearce CL, et al. Timing of births and oral contraceptive use influences OC risk. Int J Cancer. 2017;141:2392–9. https://doi.org/10.1002/ijc.30910.CrossRefPubMedPubMedCentral

27.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. https://doi.org/10.1093/nar/28.1.27.CrossRefPubMedPubMedCentral

28.

Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51. https://doi.org/10.1002/pro.3715.CrossRefPubMedPubMedCentral

29.

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92. https://doi.org/10.1093/nar/gkac963.CrossRefPubMed

30.

Chen S, Yu Q, Zhou S. Plasmatic levels of HSP90α at diagnosis: a novel prognostic indicator of clinical outcome in advanced lung cancer patients treated With PD-1/PD-L1 inhibitors plus chemotherapy. Front Oncol. 2021. https://doi.org/10.3389/fonc.2021.765115.CrossRefPubMedPubMedCentral

31.

Chen J, Zhan C, Zhang L, et al. The Hypermethylation of Foxp3 Promoter Impairs the Function of Treg Cells in EAP. Inflammation. 2019;42(5):1705–18. https://doi.org/10.1007/s10753-019-01030-0.CrossRefPubMed

32.

Suo C, Hrydziuszko O, Lee D, et al. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival. Bioinformatics. 2015;31(16):2607–13. https://doi.org/10.1093/bioinformatics/btv164.CrossRefPubMed

33.

Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA. Combination therapies with HSP90 inhibitors against colorectal cancer. Biochim Biophys Acta Rev Cancer. 2019;1871(2):240–7. https://doi.org/10.1016/j.bbcan.2019.01.002.CrossRefPubMed

34.

Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod. 1998;3(2):86–95. https://doi.org/10.1530/ror.0.0030086.CrossRefPubMed

35.

Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65(6):2162–9. https://doi.org/10.1158/0008-5472.CAN-04-3924.CrossRefPubMed

36.

Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of OC. Tumour Biol. 2010;31(2):113–9. https://doi.org/10.1007/s13277-009-0015-y.CrossRefPubMed

37.

Yano M, Naito Z, Yokoyama M, et al. Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett. 1999;137(1):45–51. https://doi.org/10.1016/s0304-3835(98)00338-3.CrossRefPubMed

38.

Becker B, Multhoff G, Farkas B, et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol. 2004;13(1):27–32. https://doi.org/10.1111/j.0906-6705.2004.00114.x.CrossRefPubMed

39.

Biaoxue R, Xiling J, Shuanying Y, et al. Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res. 2012;31(1):70. https://doi.org/10.1186/1756-9966-31-70.CrossRefPubMedPubMedCentral

40.

Gonzalez M, De Brasi C, Ferri C, Bengió R, Bianchini M, Larripa I. CAMKIIγ, HSP70 and HSP90 transcripts are differentially expressed in chronic myeloid leukemia cells from patients with resistant mutated disease. Leuk Lymphoma. 2014;55(9):2101–8. https://doi.org/10.3109/10428194.2013.861070.CrossRefPubMed

41.

Wu Y, Huang B, Liu Q, Liu Y. Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients. Int J Clin Exp Pathol. 2015;8(7):8252–9. Published 2015 Jul 1.PubMedPubMedCentral

42.

Bekki H, Kohashi K, Maekawa A, et al. Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma. BMC Cancer. 2015;15:804. https://doi.org/10.1186/s12885-015-1830-8. Published 2015 Oct 26.CrossRefPubMedPubMedCentral

43.

Song CH, Park SY, Eom KY, et al. Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers. Breast Cancer Res. 2010;12(2):R20. https://doi.org/10.1186/bcr2557.CrossRefPubMedPubMedCentral

44.

Kocsis J, Madaras B, Tóth EK, Füst G, Prohászka Z. Serum level of soluble 70-kD heat shock protein is associated with high mortality in patients with colorectal cancer without distant metastasis. Cell Stress Chaperones. 2010;15(2):143–51. https://doi.org/10.1007/s12192-009-0128-7.CrossRefPubMed

45.

Ajili F, Nedri A, Kourda N, et al. Prognostic Significance of Heat Shock Protein 90 in Non Muscle Invasive Bladder Cancer Treated by BCG Immunotherapy. J Cytol Histol. 2014;5(3):3–6.CrossRef

46.

Tsutsumi S, Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci. 2007;98(10):1536–9. https://doi.org/10.1111/j.1349-7006.2007.00561.x.CrossRefPubMed

47.

Johnson JL, Toft DO. A novel chaperone complex for steroid receptors involving heat shock proteins, immunophilins, and p23. J Biol Chem. 1994;269(40):24989–93.CrossRefPubMed

48.

Roe SM, Prodromou C, O’Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem. 1999;42(2):260–6. https://doi.org/10.1021/jm980403y.CrossRefPubMed

49.

Porter JR, Ge J, Lee J, Normant E, West K. Ansamycin inhibitors of Hsp90: nature’s prototype for anti-chaperone therapy. Curr Top Med Chem. 2009;9(15):1386–418. https://doi.org/10.2174/156802609789895719.CrossRefPubMed

50.

Soga S, Akinaga S, Shiotsu Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des. 2013;19(3):366–76. https://doi.org/10.2174/138161213804143617.CrossRefPubMed

51.

Shringarpure R, Catley L, Bhole D, et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006;134(2):145–56. https://doi.org/10.1111/j.1365-2141.2006.06132.x.CrossRefPubMed

52.

Qin DJ, Tang CX, Yang L, et al. Hsp90 is a novel target molecule of CDDO-Me in inhibiting proliferation of OC Cells. PLoS One. 2015;10(7):e0132337. https://doi.org/10.1371/journal.pone.0132337.CrossRefPubMedPubMedCentral

Title: Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center
Authors: Cancan Duan
KuoKuo Li
Xiaohua Pan
Zhaolian Wei
Lan Xiao
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10929-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle

Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker

Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study

Fusobacterium nucleatum facilitates proliferation and autophagy by activating miR-361-3p/NUDT1 axis through oxidative stress in hypopharyngeal squamous cell carcinoma

Analysis of connexin 43, connexin 45 and N-cadherin in the human sertoli cell line FS1 and the human seminoma-like cell line TCam-2 in comparison with human testicular biopsies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer